https://www.selleckchem.com/products/ml364.html
As a result, co-treatment of meloxicam and lipopolysaccharide inhibited (P 0.05). Meloxicam inhibited (P less then 0.05) the lipopolysaccharide-activated Wnt/β-catenin pathway by reducing (P less then 0.05) the protein levels of β-catenin, c-Myc, cyclin D1, and glycogen synthase kinase-3β and prevented the lipopolysaccharide-induced β-catenin from entering the nucleus. Meloxicam suppressed (P less then 0.05) the phosphorylation of PI3K and AKT. In conclusion, meloxicam alone did not influence the cell cycle progression or the cell prolife
Like
Comment
Share
